A retrospective analysis of clinical outcomes between hospitalized patients with COVID‐19 who received famotidine or pantoprazole

BACKGROUND AND AIM: There is limited research on the use of histamine‐H2 receptor antagonists and proton pump inhibitors for treating COVID‐19. We compare clinical outcomes between patients hospitalized with COVID‐19 receiving famotidine or pantoprazole. METHODS: This retrospective study included 21...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Justin J., St. Cyr, Nikolas, Douen, Aaron, Fogel, Joshua, Trillo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366487/
https://www.ncbi.nlm.nih.gov/pubmed/37496815
http://dx.doi.org/10.1002/jgh3.12905
Descripción
Sumario:BACKGROUND AND AIM: There is limited research on the use of histamine‐H2 receptor antagonists and proton pump inhibitors for treating COVID‐19. We compare clinical outcomes between patients hospitalized with COVID‐19 receiving famotidine or pantoprazole. METHODS: This retrospective study included 2184 patients (famotidine: n = 638, pantoprazole: n = 727, nonuse: n = 819) aged 18 years or older treated for COVID‐19 from March 2020 to March 2021. Patients who received both famotidine and pantoprazole treatments were excluded. Multivariate logistic regression was used for the primary outcome, namely all‐cause mortality, and the secondary outcomes, namely mechanical ventilation, vasopressor use, acute kidney injury, and gastrointestinal bleeding. The main predictor variable was the use of famotidine or pantoprazole. Covariates were demographics, chronic diseases, and symptoms. RESULTS: As compared to nonuse, famotidine (OR: 0.30, 95% CI: 0.20–0.44, P < 0.001) and pantoprazole (OR: 0.47, 95% CI: 0.33–0.66, P < 0.001) were significantly associated with lower odds for all‐cause mortality. Comparison of famotidine and pantoprazole showed that the former had lower odds for all‐cause mortality (OR: 0.65, 95% CI:0.45–0.95, P < 0.05), mechanical ventilation (OR: 0.38, 95% CI: 0.25–0.58, P < 0.001), vasopressor use (OR: 0.33, 95% CI: 0.22–0.48, P < 0.001), acute kidney injury (OR: 0.40, 95% CI: 0.30–0.54, P < 0.001), and gastrointestinal bleeding (OR: 0.15, 95% CI: 0.08, 0.29, P < 0.001). CONCLUSIONS: Famotidine is associated with lower odds for all‐cause mortality, mechanical ventilation, vasopressor use, acute kidney injury, and gastrointestinal bleeding as compared to pantoprazole in patients hospitalized with COVID‐19. We recommend that clinicians consider the use of famotidine over pantoprazole for hospitalized COVID‐19 patients. Future research with a clinical trial would be beneficial to further support such use of famotidine.

Ejemplares similares